Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | OAT | P04181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835404 | 0.76 | MCL1 (0.36) | SIRT1KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL6622419 | 0.73 | — | — | |
| SCHEMBL22468834 | 0.70 | — | — | |
| SCHEMBL932332 | 0.70 | — | — | |
| SCHEMBL14875376 | 0.68 | OAT (0.36) | SIRT1KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL8741700 | 0.68 | — | — | |
| SCHEMBL6865407 | 0.68 | MCL1 (0.34) | SIRT1KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL20104017 | 0.67 | KDM4E (0.42) | SIRT1KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL5251694 | 0.67 | KDM4E (0.42) | SIRT1KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL17925154 | 0.67 | SIRT1 (0.33) | SIRT1KDM4EPOLBL3MBTL1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | SIRT1 950/4885KDM4E 3525/4885POLB 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.